Silence Therapeutics (SLN) Change in Receivables (2020 - 2025)
Silence Therapeutics recorded quarterly Change in Receivables of -$30000.0 in Q4 2025, up 51.61% quarter-over-quarter from -$62000.0 in Q3 2025, and down 104.91% year-over-year from $611000.0 in Q4 2024.
Silence Therapeutics' Change in Receivables history runs 6 years deep, the most recent figure standing at -$30000.0 for Q4 2025.
- In Q4 2025, Change in Receivables fell 104.91% year-over-year to -$30000.0; the TTM figure through Mar 2026 stood at -$84000.0 (down 100.89% YoY), while the FY2025 annual figure was -$1.0 million, down 213.27% from the prior year.
- Change in Receivables came in at -$30000.0 for Q4 2025 at Silence Therapeutics, up from -$62000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $46.5 million in Q2 2021 to a low of -$13.8 million in Q2 2023.
- A 5-year average of $2.9 million and a median of -$11000.0 in 2025 frame the typical range for Change in Receivables.
- Across the five-year window, Change in Receivables tumbled 3243.59% in 2023 and surged 1158.72% in 2024, its largest moves.
- Silence Therapeutics' Change in Receivables stood at -$2.5 million in 2021, then soared by 62.53% to -$920748.7 in 2022, then jumped by 131.54% to $290429.5 in 2023, then surged by 110.38% to $611000.0 in 2024, then plunged by 104.91% to -$30000.0 in 2025.
- According to Business Quant data, Change in Receivables over the past three periods registered -$30000.0, -$62000.0, and $8000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -30,000.00 |
| Dec 31, 2025 | -30,000.00 |
| Sep 30, 2025 | -62,000.00 |
| Sep 30, 2025 | -62,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Mar 31, 2025 | -940,000.00 |
| Mar 31, 2025 | -940,000.00 |
| Dec 31, 2024 | 611,000.00 |
| Dec 31, 2024 | 611,000.00 |
| Sep 30, 2024 | 1.80 Mn |
| Sep 30, 2024 | 1.80 Mn |
| Jun 30, 2024 | 7.95 Mn |
| Jun 30, 2024 | 7.95 Mn |
| Mar 31, 2024 | 10.01 Mn |
| Mar 31, 2024 | 10.01 Mn |
| Dec 31, 2023 | 290,429.54 |
| Dec 31, 2023 | 290,429.54 |
| Sep 30, 2023 | 15.02 Mn |
| Sep 30, 2023 | 15.02 Mn |
| Jun 30, 2023 | -13.77 Mn |
| Jun 30, 2023 | -13.77 Mn |
| Mar 31, 2023 | -945,666.41 |
| Mar 31, 2023 | -945,666.41 |
| Dec 31, 2022 | -920,748.73 |
| Dec 31, 2022 | -920,748.73 |
| Sep 30, 2022 | 3.27 Mn |
| Sep 30, 2022 | 3.27 Mn |
| Jun 30, 2022 | -411,795.74 |
| Jun 30, 2022 | -411,795.74 |
| Mar 31, 2022 | -3.01 Mn |
| Mar 31, 2022 | -3.01 Mn |
| Dec 31, 2021 | -2.46 Mn |
| Dec 31, 2021 | -2.46 Mn |
| Sep 30, 2021 | 603,819.51 |
| Sep 30, 2021 | 603,819.51 |
| Jun 30, 2021 | 46.50 Mn |
| Jun 30, 2021 | 46.50 Mn |
| Mar 31, 2021 | -6.06 Mn |
| Mar 31, 2021 | -6.06 Mn |
| Dec 31, 2020 | 3.44 Mn |
| Dec 31, 2020 | 3.44 Mn |
| Sep 30, 2020 | 1.31 Mn |
| Sep 30, 2020 | 1.31 Mn |